Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that has re-emerged in recent decades, causing large-scale epidemics in many parts of the world. CHIKV infection leads to a febrile disease known as chikungunya fever (CHIKF), which is characterised by severe joint pain and myalgia. As many patients develop a painful chronic stage and neither antiviral drugs nor vaccines are available, the development of a potent CHIKV inhibiting drug is crucial for CHIKF treatment. A comprehensive summary of current antiviral research and development of small-molecule inhibitor against CHIKV is presented in this review. We highlight different approaches used for the identification of such compounds and further discuss the identification and application of promising viral and host targets.

show abstract

“…infection stages of the CHIKV replication cycle. Nevertheless, the precise mode of action remains unknown [211].…”

Section: Undefined Targetsmentioning

confidence: 99%

“…A mechanism of action study suggests that the compounds act in the early stages and in some post-infection stages of the CHIKV replication cycle. Nevertheless, the precise mode of action remains unknown [ 211 ].…”

Section: Undefined Targetsmentioning

confidence: 99%

Antivirals against the Chikungunya Virus

Battisti

Urban

Langer

2021

Viruses

View full text Add to dashboard Cite

show abstract

“…Ribavirin, favipiravir, arbidol have elicited promising results in cell linebased studies or animal models [16,24,25,28]. The patent on suramin claims it to be effective anti-CHIKV agent in both cell line and animal models [29,51]. Although, the granted patents for CHIKV inhibitors are limited; therefore, further exploration of anti-CHIKV molecules is required.…”

Section: Expert Opinionmentioning

confidence: 99%

Antiviral therapeutics for chikungunya virus

Ghildiyal

Gabrani

2020

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Introduction: Chikungunya virus (CHIKV), a reemerging human arthropod borne virus, can causes global epidemic outbreaks and has become a serious health concern due to the unavailability of any antiviral therapy/vaccine. Extensive research has been conducted to target different proteins from CHIKV to curtail the spread of virus. Areas covered: This review provides an overview of the granted patents including the current status of antiviral strategies targeting CHIKV. Expert opinion: Under the current scenario, potential molecules and different approaches have been utilized to suppress CHIKV infection. MV-CHIKV and VRC-CHKVLP059-00-VP vaccine candidates have successfully completed phase I clinical trials and ribavirin (inhibitor) has shown significant inhibition of CHIKV replication and could be the most promising candidates. The drug resistance and toxicity can be modulated by using the inhibitors/drugs in combination. Moreover, nanoparticle formulations can improve the efficacy and bioavailability of drugs.

show abstract

“…The copyright holder for this this version posted October 20, 2020. ; https://doi.org/10.1101/2020.10.15.20213603 doi: medRxiv preprint group into the piperazine moiety of fluoroquinolone changed its activity from antibacterial to antiviral, with specific effects on human immunodeficiency virus (HIV) (8). Antiviral activity is confirmed by dose-dependently inhibiting viral RNA production (9).…”

Section: Penicillinsmentioning

confidence: 99%

“…And their antiviral activity is identified by inhibition of viral RNA production in a dose-dependent manner (7,8). They also can be considered excellent candidates for the development of anti-Zika virus and anti-chikungunya virus (CHIKV) agents (9). It seems that trimethoprim-sulfamethoxazole suppress human immunodeficiency viral load and provide an excellent clinical response to antiretroviral therapy for HIV (10).…”

Section: Introductionmentioning

confidence: 99%

Risks and Benefits of Antibiotics vs. COVID-19 Morbidity and Mortality

Tanioka¹,

Tanioka²

2020

Preprint

View full text Add to dashboard Cite

The purpose is to analyze the potential association of each antibiotic consumption rate and use ratio with COVID-19 morbidity and mortality, and to investigate the efficacy and safe use of antibiotics against COVID-19. Design Retrospective statistical analysis of antibiotic use compared with COVID-19 morbidity and mortality. Methods Each antibiotic defined daily dose per 1000 inhabitants per day as each antibiotic consumption rate was available in the official reports and each antibiotic use ratio data was calculated from them. Coronavirus disease data were obtained from the WHO Coronavirus Disease Dashboard. The relationships between the sum of defined daily dose, each antibiotic defined daily dose, each antibiotic use ratio, and COVID-19 morbidity and mortality were examined. The statistical correlation was calculated by univariate linear regression analysis and expressed by Pearson's correlation coefficient. Results Cephalosporins were a negative correlation with mortality and morbidity. Penicillin had a weak positive correlation with them. Macrolides, quinolone, and sulfonate showed a slightly negative correlation tendency with mortality. Conclusions Cephalosporins may affect less morbidity and mortality. Penicillin suggests to accelerate them. The combination of cephalosporins with macrolides or quinolones may be a helpful treatment.

show abstract

Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors

Cited by 17 publications

References 28 publications

Antivirals against the Chikungunya Virus

Antivirals against the Chikungunya Virus

Antiviral therapeutics for chikungunya virus

Risks and Benefits of Antibiotics vs. COVID-19 Morbidity and Mortality

Contact Info

Product

Resources

About